pantogab (hopantenic acid)

RN given refers to cpd without isomeric designation; synonym hopantenic acid refers to (R)-isomer; synonym pantogam refers to Ca salt (2:1), ((R)-isomer

Also Known As:

hopantenic acid; GABA pantoate; GABA-pantoyl; calcium homopantothenate; calcium hopantenate; homopantothenic acid; pantogab, (+-)-isomer; pantogab, (R)-isomer; pantogab, (S)-isomer; pantogab, calcium (2:1) salt; pantogab, calcium (2:1) salt, (R)-isomer; pantogab, sodium salt, (R)-isomer; pantogam; pantoyl-GABA

Networked: 60 relevant articles (8 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Zavadenko, N N: 3 articles (01/2019 - 01/2011)
2.	Medvedev, V E: 3 articles (01/2015 - 01/2012)
3.	Guzeva, V I: 2 articles (01/2019 - 01/2015)
4.	Frolova, V I: 2 articles (01/2015 - 01/2014)
5.	Epifanov, A V: 2 articles (01/2014 - 01/2012)
6.	Abdulkadyrova, M Zh: 2 articles (11/2006 - 09/2002)
7.	Borisova, S A: 2 articles (11/2006 - 09/2002)
8.	Davydova, N G: 2 articles (11/2006 - 09/2002)
9.	Gorshkova, I A: 2 articles (09/2002 - 05/2001)
10.	Kondrakhin, E A: 1 article (09/2021)

Related Diseases

1.	Amnesia (Dissociative Amnesia) 07/01/1987 - "Calcium hopantenate and dihydroergotoxine also showed cerebral-activating properties in the majority of behavioral and electroencephalographic paradigms; however neither improved scopolamine-induced amnesia and calcium hopantenate had no effects on learning. " 05/01/1987 - "GABAergic agents (sodium oxybutyrate, phenibut, pantogam), gutimine, nicotinoyl-GABA eliminated amnesia to a lesser extent. "
2.	Schizophrenia (Dementia Praecox) 01/01/2015 - "[Augmented antipsychotic therapy with pantogam active in patients with schizophrenia]." 01/01/2017 - "[A differential approach to the improvement of prevention and correction of neuroleptic side extrapyramidal disorders with pantogam activ in patients with schizophrenia]." 01/01/2015 - "to study the efficacy of the GABA-ergic drug pantogam active (D-, L-gopantenic acid) in patients with schizophrenia treated with typical neuroleptics and to assess the rate of treatment response and tolerability of the drug. " 01/01/1979 - "A study of 246 patients (with schizophrenia, manic depressive psychoses and psychoorganic syndrome) treated by some drugs of a metabolic action (encephalotropic", "nootropic" drugs, piracetam, piriditol and pantogam) permitted one to determine the place of these preparations in a comprehensive treatment of mental disorders. " 01/01/2017 - "Pantogam active, having also an additional anxiolytic effect, is characterized by bimodal activity, improves not only cognitive functions, but also emotional state in patients in psychiatric, neurological and cardiological practice with such diseases and conditions as anxiety/anxiety-depressive disorders, chronic brain ischemia, ischemic heart disease, chronic heart failure, arterial hypertension, epilepsy, craniocerebral trauma, schizophrenia as well as cognitive impairment in the structure of neurological and psychogenic deficiencies. "
3.	Cognitive Dysfunction 01/01/2009 - "[The use of pantogam in patients with moderate cognitive disorders of vascular genesis]." 01/01/2015 - "An analysis of cognitive impairment in children of the comparison group and in the main group before and after treatment with pantogam was performed using a set of neurocognitive tests (the Luscher Color Test, «Piano playing test», «Three word test» and «Four is redundant test»). " 01/01/2016 - "The rapid and reliable reduction of anxiety, depression and cognitive impairment during concomitant therapy with antidepressants and pantogam activ was identified. " 01/01/2015 - "To study cognitive impairment and the efficacy of hopantenic acid (pantogam) in children, aged from 4 to 7 years, with epilepsy and cognitive impairment. " 01/01/2017 - "Pantogam active, having also an additional anxiolytic effect, is characterized by bimodal activity, improves not only cognitive functions, but also emotional state in patients in psychiatric, neurological and cardiological practice with such diseases and conditions as anxiety/anxiety-depressive disorders, chronic brain ischemia, ischemic heart disease, chronic heart failure, arterial hypertension, epilepsy, craniocerebral trauma, schizophrenia as well as cognitive impairment in the structure of neurological and psychogenic deficiencies. "
4.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/01/2023 - "To evaluate the therapeutic efficacy of Pantogam aktiv in the treatment of clinical manifestations of burnout in mothers of children with ADHD. " 01/01/2017 - "There was a trend towards an increase in the percentage of patients with positive changes (a decrease in the total ADHD-DSM-IV by ≥25%) in the end of the 3rd and 4th month in the pantogam group (treatment response was 66.7 and 68.9%, respectively) compared to the placebo group (treatment response was 52.3 and 61.4%, respectively). " 01/01/2017 - "[Pharmacotherapy of attention deficit hyperactivity disorder in children: the results of a multicenter double-blind placebo-controlled study of hopantenic acid]." 01/01/2017 - "To assess the efficacy and safety of hopantenic acid (pantogam) compared to placebo in the treatment of attention deficit hyperactivity disorder (ADHD) in children, aged from 6 to 12 years, during 4 month in the prospective multicenter comparative double-blind placebo-controlled study in parallel groups. " 09/01/2021 - "The closed enriched cross maze test was employed as a new experimental model of the attention deficit disorder (ADD) for evaluation of the behavioral and neurochemical effects of the nootropic drug pantogam (100 mg/kg, intraperitoneally) and atomoxetine hydrochloride (3 mg/kg, intraperitoneally) administered subchronically to CD-1 outbred mice. "
5.	Epilepsy (Aura) 01/01/2015 - "The study included 40 children with epilepsy treated with pantogam (the main group) and 23 children with epilepsy who did not receive pantogam (the comparison group). " 01/01/2015 - "To study cognitive impairment and the efficacy of hopantenic acid (pantogam) in children, aged from 4 to 7 years, with epilepsy and cognitive impairment. " 01/01/2017 - "Pantogam active, having also an additional anxiolytic effect, is characterized by bimodal activity, improves not only cognitive functions, but also emotional state in patients in psychiatric, neurological and cardiological practice with such diseases and conditions as anxiety/anxiety-depressive disorders, chronic brain ischemia, ischemic heart disease, chronic heart failure, arterial hypertension, epilepsy, craniocerebral trauma, schizophrenia as well as cognitive impairment in the structure of neurological and psychogenic deficiencies. "

Related Drugs and Biologics

1.	pantogab (hopantenic acid)
2.	Dihydroergotoxine (Hydrogenated Ergot Alkaloids)
3.	gamma-Aminobutyric Acid (GABA)
4.	4-amino-3-phenylbutyric acid (phenibut)
5.	Antipsychotic Agents (Antipsychotics)
6.	Acids
7.	nicotinoyl-GABA (Picamilon)
8.	sufoxazine (teniloxazine)
9.	Scopolamine (Hyoscine)
10.	GABA Agents

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Aftercare (After-Treatment)
4.	Massage (Zone Therapy)